Search | Clinical Trials Finder

Conditions: Limb-girdle Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more

Conditions: Cardiomyopathy, Heart Failure, Congestive, Thoracic Surgery
Interventions: Atrial synchronous bi-ventricular pacing; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Ischemic and Nonischemic Cardiomyopathy, With Primary and Secondary Implant Indications
Interventions: Not listed
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Duchenne Muscular Dystrophy
Interventions: eplerenone, placebo; Drug
Lead sponsor: Subha Raman; Other
Eligibility: 7 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio

Conditions: Cardiomyopathy, Renal Impairment
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiomyopathies, Heart Failure, Non-left Bundle Branch Block, Cardiac Resynchronization Therapy
Interventions: CRT-D implantation; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Amyloid Cardiomyopathy, Transthyretin-Related
Interventions: Acoramidis (AG10); Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 26
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: TN-201; Genetic
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 10
States / cities: La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more

Conditions: Non-obstructive Hypertrophic Cardiomyopathy
Interventions: Ninerafaxstat 200mg MR, Placebo; Drug
Lead sponsor: Imbria Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 18 more

Conditions: LMNA-Related Dilated Cardiomyopathy
Interventions: NVC-001 - Low Dose, NVC-001 - Intermediate Dose, NVC-001 - High Dose; Genetic
Lead sponsor: Nuevocor Pte. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
Interventions: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN, Prednisone; Biological · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 12 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiomyopathy
Interventions: Ranolazine; Drug
Lead sponsor: Cardiovascular Institute of the South Clinical Research Corporation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Lafayette, Louisiana

Conditions: Sudden Cardiac Death
Interventions: Not listed
Lead sponsor: Pocono Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: East Stroudsburg, Pennsylvania

Conditions: Hypertrophic Cardiomyopathy
Interventions: pacemaker implantation, percutaneous transluminal septal ablation (PTSA); Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiomyopathy, Heart Failure, Cardiac Arrhythmia
Interventions: Standard Defibrillation Testing, Upper Limit of Vulnerability Testing; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 30 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ischemic Cardiomyopathy
Interventions: Impella 5.5 with SmartAssist Supported OPCABG; Device
Lead sponsor: Lucian Archambault Durham III; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: AI Toolkit for ATTR-CM Diagnosis; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 1,500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Detroit, Michigan + 8 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions: ISCDX blood test; Diagnostic Test
Lead sponsor: Ischemia Care LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cardiomyopathy Due to Anthracyclines
Interventions: Allo-MSCs, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Stanford, California • Gainesville, Florida • Miami, Florida + 4 more

Conditions: Cardiomyopathy, Hypertrophic
Interventions: Mavacamten, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more

Conditions: Friedreich Ataxia, Cardiomyopathy
Interventions: Not listed
Lead sponsor: Lexeo Therapeutics; Industry
Eligibility: 6 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: La Jolla, California • Tampa, Florida • Indianapolis, Indiana + 5 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: on-pump intracardiac echocardiography; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery

A Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

Factors Associated With Response to Cardiac Resynchronization Therapy in Heart Failure Patients With Non-LBBB ECG Pattern

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

An Open-label Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

Study of Paced QRS Duration as a Marker of Sudden Cardiac Death

A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy

Evaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation

Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study

Impella Supported OPCABG

An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

Functional Capacity and Quality of Life Following Septal Myectomy in Patients With HCM

Biomarkers of Acute Stroke in Clinic

Stem Cell Injection in Cancer Survivors

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Clinical Course Of Disease In Participants With FA-CM

OPIE in the Thin Interventricular Septum